- Home
- OACC vs IMMP Comparison
OACC vs IMMP Comparison
Compare OACC & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OACC
- IMMP
- Stock Information
- Founded
- OACC 2024
- IMMP 1987
- Country
- OACC United States
- IMMP Australia
- Employees
- OACC N/A
- IMMP N/A
- Industry
- OACC
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- OACC
- IMMP Health Care
- Exchange
- OACC NYSE
- IMMP Nasdaq
- Market Cap
- OACC 249.4M
- IMMP 211.1M
- IPO Year
- OACC 2024
- IMMP N/A
- Fundamental
- Price
- OACC $10.45
- IMMP $1.85
- Analyst Decision
- OACC
- IMMP Buy
- Analyst Count
- OACC 0
- IMMP 2
- Target Price
- OACC N/A
- IMMP $8.50
- AVG Volume (30 Days)
- OACC 78.0K
- IMMP 645.2K
- Earning Date
- OACC 01-01-0001
- IMMP 05-16-2025
- Dividend Yield
- OACC N/A
- IMMP N/A
- EPS Growth
- OACC N/A
- IMMP N/A
- EPS
- OACC N/A
- IMMP N/A
- Revenue
- OACC N/A
- IMMP $3,019,249.00
- Revenue This Year
- OACC N/A
- IMMP $11.25
- Revenue Next Year
- OACC N/A
- IMMP $10.22
- P/E Ratio
- OACC $96.45
- IMMP N/A
- Revenue Growth
- OACC N/A
- IMMP 24.11
- 52 Week Low
- OACC $9.95
- IMMP $1.32
- 52 Week High
- OACC $10.85
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- OACC N/A
- IMMP 53.09
- Support Level
- OACC N/A
- IMMP $1.44
- Resistance Level
- OACC N/A
- IMMP $2.71
- Average True Range (ATR)
- OACC 0.00
- IMMP 0.18
- MACD
- OACC 0.00
- IMMP 0.03
- Stochastic Oscillator
- OACC 0.00
- IMMP 28.93
About OACC OAKTREE ACQUISITION CORP III LIFE S
Oaktree Acquisition Corp III Life Sciences is a blank check company.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.